Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Oncology grew 7% in Q2 despite continued COVID-19 impact +7% 3.9 3.5 0.1 Oncology net sales USD bn, % cc Launches1 Growth drivers² Base business, Gx3 Solid Q2 performance fueled by growth drivers and recent launches ■ Growth drivers and recent launches now constitute 50% of sales (up from 45% Q2 2020) Key drivers: 0.1 1.5 1.8 +19% - Kisqali® Q2 sales USD 225m, +36% JakaviⓇ Q2 sales USD 398m, +19% 2.0 2.0' -3% - KymriahⓇ Q2 sales USD 147m, +19% Q2 2020 Q2 2021 - +4% 7.7 7.2 0.2 0.3 PromactaⓇ/Revolade® Q2 sales USD 513m, +18% ■ COVID-19 continues to impact diagnosis and treatment rates in certain segments (e.g. hospital-initiated therapies and breast cancer) Ongoing Gx impact including Glivec®, Exjade®/JadenuⓇ, AfinitorⓇ 2.9 3.5 +17% 4.1 3.91 -6% H1 2021 H1 2020 1. Launches include Piqray®, Adakveo® and TabrectaⓇ 2. Growth drivers include PromactaⓇ/Revolade®, Tafinlar+ MekinistⓇ, Kisqali®, LutatheraⓇ, KymriahⓇ and JakaviⓇ (marketed by Novartis ex-US). 3. Base business - other brands. Gx include AfinitorⓇ, Exjade® / JadenuⓇ, GlivecⓇ and SandostatinⓇ All % growth relate to cc unless otherwise stated. 26 Investor Relations | Q2 2021 Results ✓ NOVARTIS | Reimagining Medicine

View entire presentation